PriceTargets.com logo

Akouos - AKUS Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$13.29 As of 01/3/2023 01:00 AM ET
+0 (0.00%)
Get New Akouos Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKUS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKUS

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Akouos in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $13.29.

This chart shows the closing price for AKUS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Akouos. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/18/2022William BlairDowngradeOutperform ➝ Market PerformLow
10/18/2022Piper SandlerDowngradeOverweight ➝ Neutral$18.00 ➝ $13.00Low
10/18/2022HC WainwrightDowngradeBuy ➝ NeutralLow
9/29/2022William BlairInitiated CoverageOutperform ➝ Outperform$12.00Low
5/17/2022Piper SandlerLower TargetOverweight$40.00 ➝ $18.00Medium
4/27/2021HC WainwrightInitiated CoverageBuy$25.00High
3/30/2021Bank of AmericaDowngradeBuy ➝ Neutral$24.00 ➝ $20.00High
7/21/2020Bank of AmericaInitiated CoverageBuy$24.00High
7/21/2020BTIG ResearchInitiated CoverageBuy$35.00High
7/21/2020Piper SandlerInitiated CoverageOverweight$40.00High
7/21/2020CowenInitiated CoverageOutperformHigh
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Akouos logo
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Read More

Today's Range

Now: $13.29
Low: $13.29
High: $13.29

50 Day Range

MA: $13.29
Low: $13.29
High: $13.29

52 Week Range

Now: $13.29
Low: $2.32
High: $13.60

Volume

440 shs

Average Volume

344,411 shs

Market Capitalization

$490.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Akouos?

The following Wall Street analysts have issued stock ratings on Akouos in the last year:
View the latest analyst ratings for AKUS.

What is the current price target for Akouos?

0 Wall Street analysts have set twelve-month price targets for Akouos in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Akouos in the next year.
View the latest price targets for AKUS.

What is the current consensus analyst rating for Akouos?

Akouos currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AKUS.

What other companies compete with Akouos?

Other companies that are similar to Akouos include Arbutus Biopharma, Oculis, KalVista Pharmaceuticals, Applied Therapeutics and COMPASS Pathways. Learn More about companies similar to Akouos.

How do I contact Akouos' investor relations team?

Akouos' physical mailing address is 645 SUMMER STREET SUITE 200, BOSTON MA, 02210. The company's listed phone number is 857-410-1818 and its investor relations email address is [email protected]. The official website for Akouos is www.akouos.com. Learn More about contacing Akouos investor relations.